CDC25B2, a protein tyrosine phosphatase closely related to the putative CDC25B oncogene, was identi®ed in a Burkitt lymphoma cDNA library. CDC25B2 diers from CDC25B by a 14 residue insertion and a 41 residue deletion, which are both located in the amino-terminal region of the protein, upstream of the catalytic domain. Examination of the genomic sequence revealed that CDC25B1 (formerly B) and CDC25B2 are splice variants of the same gene. A third variant, CDC25B3, that carries both the 14 and the 41 residue sequences was also identi®ed in the same cDNA library. All three variants were detected in a panel of human primary culture and cell lines, although at dierent levels. In primary ®broblasts and in HeLa cells the CDC25B expression is cell cycle regulated, reaching a maximum in G 2 -phase. In vitro, CDC25B1 phosphatase is slightly more active than CDC25B2 and B3. However, episomal overexpression of the three CDC25B variants in ®ssion yeast reveals that in vivo, CDC25B2 is largely more active than either B1 or B3 (B24B34B1) both to complement a thermosensitive S pombe CDC25 activity and to act as a mitotic inducer. Alternative splicing of CDC25B may therefore contribute to the control of cell proliferation.
Introduction
The eukaryotic cell cycle is controlled by a family of cyclin-dependent kinases (CDKs) that regulate its key transitions. Their activities are regulated at dierent levels (Morgan, 1995) . Firstly, as the name implies, association with a cyclin regulatory subunit is a general feature of all members of the CDK family (Draetta, 1993) . For instance, a complex formed by association of CDC2 and cyclin B plays an essential role at the G 2 / M transition. It has recently been shown that the activity of CDK/cyclin complexes is also regulated by speci®c inhibitors called cyclin-dependent kinase inhibitors (CKI) that appear to play essential roles in the transduction of extra-or intra-cellular signals such as DNA damage (Elledge and Harper, 1994) to the cell cycle machinery.
Another major regulatory mechanism is the phosphorylation/dephosphorylation state of critical threonine and tyrosine residues that are located within the CDK ATP-binding site (Gould and Nurse, 1989; Morgan, 1995) . Tyrosine phosphorylation is ensured by the wee1 tyrosine kinase or related kinases that were ®rst identi®ed in yeast (Booher et al., 1993; Russell and Nurse, 1987) then in mammals Watanabe et al., 1995) . In ®ssion yeast, the CDC25 tyrosine phosphatase catalyses the activating dephosphorylation of the CDC2 protein kinase on tyrosine 15 and acts as an inducer of mitosis (Millar and Russell, 1992; Russell and Nurse, 1986) . In mammals, three homologues of CDC25 called CDC25A, CDC25B and CDC25C have been identi®ed so far. All three tyrosine phosphatases are able to complement the premitotic arrest of a ®ssion yeast strain carrying a thermosensitive mutation of the cdc25 gene (Galaktionov and Beach, 1991; Sadhu et al., 1990) .
In ®ssion yeast, the activity of CDC25 is regulated both at the mRNA and protein levels (Ducommun et al., 1990; Kovelman and Russell, 1996; Moreno et al., 1990) . In HeLa cells, expression of CDC25B has been reported to be low through out the cell cycle with a sharp increase in G 2 , CDC25C is predominantly expressed in G 2 Sadhu et al., 1990) and CDC25A is abundant both at the mRNA and protein levels in late G 1 (Jinno et al., 1994) . Phosphorylation of CDC25C by cdc2-cyclin B was shown and proposed to be part of the self-amplification mechanism of MPF at mitosis (Homann et al., 1993) . Similarly, cdk2/cyclinE dependent phosphorylation of CDC25A was demonstrated, indicating that a similar feed-back loop might regulate the progression in S-phase (Homan et al., 1994) . Site directed mutagenesis of the Xenopus CDC25C homologue was performed to identify the cdc2 phosphorylation sites. This study pointed out ®ve serine and threonine residues, elimination of which blocked the initiation of M-phase (Izumi and Maller, 1993) . These residues are all located in the amino terminal part of the phosphatase and are mostly conserved in human CDC25B and C.
CDC25A and B have been shown to be associated with the Raf1 protein kinase and with members of the 14-3-3 protein family. It has been suggested that these interactions might link the signal transduction machinery to cell cycle activation (Conklin et al., 1995; Galaktionov et al., 1995) .
An important issue is whether the abnormal regulation of positive cell cycle regulators such as CDC25 tyrosine phosphatases might be involved in oncogenic processes. Several observations favour such a possibility. Overexpression of CDC25B has been reported in two human cancer cell lines: a bladder carcinoma (T24) and SV40-transformed ®broblasts (GM637) . Transformation of human primary ®broblasts with SV40 also caused an important increase in CDC25B mRNA . More recently, in situ hybridisation studies performed on breast tumours have shown that CDC25B was overexpressed in 32% of the neoplastic tissue samples . In addition, CDC25B expression strongly correlated with microvessel density, a negative prognostic feature, and was clearly associated with a high distant recurrence rate . Finally, in rodent cells, human CDC25A and CDC25B, but not CDC25C were shown to cooperate with a mutant of Ras or with loss of Rb1 in oncogenic transformation .
Here, we report the identi®cation of three splicing variants of the human CDC25B gene. Characterisation of the properties of these three proteins indicate that alternative splicing is an important element in the regulation of their phosphatase activity in vivo. This process might therefore play an important role in the control of cell proliferation.
Results

Identi®cation of a new B-type CDC25 phosphatase
In order to identify new human cdc2 regulatory proteins, a genetic screen was performed in the ®ssion yeast Schizosaccharomyces pombe. A strain carrying the cdc25-22 thermosensitive allele was transformed with a human cDNA library made from a Burkitt lymphoma cell line (see Materials and methods). Transcription was under the control of the strong constitutive S pombe ADH promoter. At non permissive temperature (35.58C) 20 clones were obtained that complemented the de®cient ®ssion yeast CDC25 activity and allowed growth and formation of colonies.
Plasmid mapping and subsequent sequence analyses indicated that these 20 plasmids fell into three groups. Nine clones encoded the already identi®ed CDC25A tyrosine phosphatase (Galaktionov and Beach, 1991) and diered only by their 5'-length. Most of the clones lacked sequences encoding the amino terminal part of CDC25A, a domain that is only weakly conserved between dierent members of the CDC25 family and which is not necessary for catalytic activity (Xu and Burke, 1996) . Four clones have not yet been characterised. The seven remaining clones were highly homologous to the CDC25B tyrosine phosphatase and encoded full length as well as 5'-truncated version of that cDNA. However, careful mapping and full DNA sequencing of one of the longest clones revealed a number of striking dierences. Because of its high homology to CDC25B, this clone will be subsequently called CDC25B2 and we suggest the name CDC25B1 be given to the ®rst B-type CDC25 clone identi®ed (Galaktionov and Beach, 1991; .
Sequence dierences between CDC25B1 and CDC25B2
Complete nucleotide and deduced amino-acid sequences for CDC25B2 are shown in Figure 1 . Sequence dierences between CDC25B1 and B2 are indicated in Figures 1 and 2a . First, a 42 bp insertion was found at nucleotide position 199 of the open reading frame (Figure 1 ). This insertion encodes the 14 amino-acid peptide SETPKSQVGTLLFR which contains a putative CDK phosphorylation site (underlined T, boxed in Figure 2b ) that is conserved in CDC25 sequences from a number of dierent organisms (Izumi and Maller, 1993) . Second, a 123 bp deletion of a fragment spanning from nucleotide positions 418 to 541 in the CDC25B1 open reading frame led to the loss of a 41 amino-acid peptide that also carries a potential proline-directed phosphorylation site (Figure 2b ) that is again conserved in a variety of CDC25 sequences. In addition to these two major dierences, we found that in CDC25B2, the 3' untranslated region was shorter and totally diverged from CDC25B1 at nucleotide position 1978 where a stretch of polyA is located. An additional point dierence (T to A) was found in the upstream sequences at position 1962. The calculated molecular weight of CDC25B2 is 60 717 kDa (539 residues), a value close to that of CDC25B1 (63 402 kDa, 566 residues). Genomic sequence analysis reveals that CDC25B1 and CDC25B2 are splicing variants Examination of the nucleotide sequences surrounding the 42 bp insertion found in CDC25B2 revealed typical features of eukaryotic splicing sites (Horowitz and Krainer, 1994; Mount, 1982) . As shown in Figure 3a , this additional sequence is preceded and followed by the CAG motif which is the classical consensus for the 5' half of a mammalian splicing donor site (Horowitz and Krainer, 1994) . It is therefore very likely that alternative splicing of CDC25B pre-mRNA is responsible for the occurrence of the two CDC25B isoforms. The 42 bp insertion found in CDC25B2 is probably encoded by a short exon that is skipped during maturation of CDC25B mRNA. Using human genomic DNA as template and speci®c primers on both sides of the 42 bp fragment, we were unable to amplify by polymerase chain reaction any detectable fragment encompassing the CDC25B2-speci®c insertion. A likely explanation is that the intronic sequences that surround this small exon largely surpasses the polymerase chain extension capabilities.
Nucleotide analysis of the 5' and 3' regions surrounding the 123 bp sequence that is deleted in CDC25B2 suggested the existence of acceptor/donor splice sequences (Horowitz and Krainer, 1994) . We therefore used polymerase chain reaction to selectively amplify the CDC25B gene from human genomic DNA (see Methods for the sequence of the primers no. 7 and no. 8). The ampli®cation of a 186 bp cDNA region including the sequence that is deleted in CDC25B2 produced a 546 bp fragment when human genomic DNA was used as template. This genomic DNA fragment was fully sequenced (Figure 3b and accession number X96436) and reveals the presence of two introns surrounding the CDC25B2 speci®c 123 bp exon. The length of these introns are 245 bp and 105 bp respectively and their junction with the exon sequences are in agreement with eukaryotic splice sites (Horowitz and Krainer, 1994; Mount, 1982) . These results allow us to conclude that CDC25B1 and CDC25B2 are splice variants of the same gene ( Figure 3c ).
Evidence for a third CDC25B variant in the Burkitt lymphoma library
Oligonucleotides that are speci®c for the 123 bp and 42 bp insertion found in CDC25B1 and CDC25B2 respectively were designed in order to amplify selectively these two cDNA using polymerase chain reaction. Figure 4a shows a schematic view of the two CDC25B sequences with the position of the six oligonucleotides that were used in the following experiment (see Material and methods for the complete sequences of the primers). These oligos were ®rst tested with CDC25A, CDC25B1, and CDC25B2 plasmids (Figure 4b ). Oligonucleotide no. 2 together with no. 4 were speci®c for the 42 bp insertion found in CDC25B2, as this pair of primers ampli®ed a 1519 bp fragment from CDC25B2 cDNA but from neither CDC25B1 nor CDC25A (Figure 4b, left panel) . Similarly, PCR with oligonucleotide no. 3 together with no. 4 was speci®c for the insertion present in CDC25B1 but not in CDC25B2, since a 1328 bp tyrosine phosphatase family in the region were the CDC25B2 insertion (top alignment) and deletion (bottom alignment) are occurring. Sequences were ®rst aligned using the pileup program (UWGCG package) and additional corrections were subsequently made by eye with insertion of gaps to obtain the best alignment. The invariant residues are displayed in the consensus sequence (cons) with capital letters, and residues that are highly conserved are displayed in small letters. The following sequences (in the range indicated with bracketes on the right side of the ®gure) used in this study are: H sapiens CDC25B (accession number M81934 (Galaktionov and Beach, 1991) , H sapiens CDC25B2 (this study, accession number Z68092), H sapiens CDC25C (accession number M34065) (Sadhu et al., 1990) , M musculus CDC25A (accession number L16926) (Nargi and Woodford-Thomas, 1994) , M auratus (hamster) CDC25 (accession number D10878), (Seki et al., unpublished) , X laevis CDC25c (accession number M94264) (Kumagai and Dunphy, 1992) , X laevis CDC25bb (accession number M96858) (Izumi et al., 1992) , S scrofa (pig) (accession number X78317) (Cui et al., unpublished)
Splice variants of the CDC25B phosphatase V Baldin et al fragment was ampli®ed from CDC25B1 cDNA but not from CDC25B2 and CDC25A ( Figure 4b , right panel).
Oligonucleotides no. 2 and no. 3 in combination with no. 4 were subsequently used to check whether CDC25B splice variants were present in the Burkitt lymphoma cDNA library from which CDC25B2 was obtained ( Figure 4c ). A 1328 bp fragment that corresponds to a cDNA containing the CDC25B1-speci®c insertion was ampli®ed from the Burkitt library (Bk lane) using the no. 3 ± no. 4 pair of oligos ( Figure  4c ).
As expected, a fragment migrating at the same size as CDC25B2 was also detected in the library and ampli®ed with the no. 2 ± no. 4 pair of oligos but, in addition, a very abundant and slightly larger fragment was also ampli®ed. These two PCR products were further separated (Figure 4d ) then the top band was puri®ed and subjected to further ampli®cation with oligonucleotides no. 3 and no. 4. A fragment that migrated at the expected size for CDC25B1 was detected in the reampli®cation product with this combination of primers. This observation indicated that a cDNA containing both the 42 bp and 123 bp insertions was present in the library. When the PCR fragment ampli®ed with pair no. 2 ± no. 4 was sub cloned and fully sequenced it was found to encode alternatively spliced form of a CDC25B cDNA that carries both the CDC25B1-and CDC25B2-speci®c insertions. This third variant encodes a 64 946 kDa protein (580 residues) and we suggest that it be designated CDC25B3.
Only one 675 bp fragment was ampli®ed from the Burkitt cDNA library when primers no. 5 and no. 6 (located on both sides of the CDC25B catalytic domain) were used (data not shown). This fragment is identical in length to the ampli®cation product obtained with a CDC25B2 plasmid. It is therefore likely that no other splicing variants are present in our cDNA library for this part of CDC25B.
mRNA expression of CDC25B variants in dierent cell types
The relative expression of the CDC25B splicing variants was examined in human primary ®broblasts (IMR-90) and in primary retinal pigment epithelial cells (RPE) as well as in spontaneously immortalised and in transformed cells ( Figure 5 ). RT ± PCR with a pair of primers no. 9 and no. 10, (see Materials and methods for the sequences) that selectively amplify all three variants was used in this study. Figure 5a shows a schematic view of the CDC25B sequence indicating the relative position of the two primers. As shown in Figure 5b , only the CDC25B3 variant was detected in human diploid IMR90 ®broblasts and in NIH-OVCAR3 cells (lanes 1 and 7) . In contrast, the three variants were present, although at dierent levels in most of the cell lines that were examined. However, in IGROV1 and in RPE cells, the CDC25B2 mRNA was barely detectable.
Cell cycle regulation of CDC25B mRNA expression
We ®rst investigated the expression of CDC25B mRNA variants in HeLa cells that were drug-arrested at dierent stages of the cell cycle. As shown in Figure  6a , lovastatine treated cells were mostly arrested in the G 1 -phase. Hydroxyurea treated cells were arrested at G 1 /S and were in S-phase by 4 h after drug removal. From nocodazole treated cells (mostly in G 2 /M), mitosis-arrested cells were recovered in the media after plate shaking. The determination of cdc2 mRNA expression was used as an internal control. The three CDC25B variants mRNA were detected at every stage of the cell cycle. However, CDC25B3 (and B1 to a lower extend) was more abundant in nocodazole treated cells than in G 1 -and S-phase. Furthermore, in mitotic cells that were recovered by mitotic shake-o after nocodazole treatment, CDC25B1 and B2 mRNA level was also more abundant. These results suggest that expression of these three variants is increased during the G 2 -phase of the cell cycle.
We next investigated the cell cycle regulation of CDC25B3 mRNA expression in human IMR90 ®broblasts. In these cells, the CDC25B3 mRNA was found to be present in exponentially growing cells but was virtually absent from cells harvested at con¯uence (Figure 6b) . We examined the variation of expression of this variant upon serum deprivation and re-addition (Baldin et al., 1993) . The synchrony of the cell population entering S-phase was monitored in a parallel culture by BrdU incorporation (Figure 6c ). The expression of CDC25B3 mRNA was considerably reduced in 72 h serum starved cells. However, after serum re-addition (20%), a large increase in the level of CDC25B3 mRNA was detected. The pattern of accumulation of CDC25B3 mRNA showed a maximum after 28 h when most of the cells had already undergone S-phase and remained high in G 2 . In primary ®broblasts, the mRNA expression of CDC25B therefore also appears to be cell cycle regulated.
Characterisation of the CDC25B variants phosphatase activities in vitro
The CDC25B1-3 splicing variants mRNA encode proteins that are 63 402 kDa, 60 717 kDa and 64 946 kDa respectively. In vitro translated CDC25B1, B2 and B3 are all recognised by commercially available antibodies against CDC25B ( Figure  7b ). However the minor dierence in their apparent molecular weight and the presence of phosphorylated forms do not allow an accurate identi®cation of these three proteins on Western-Blot of total cellular extracts (data not shown). In order to characterise in vitro the phosphatase activity of the three CDC25B splicing variants, their cDNAs were cloned in a pGEX vector and fusion proteins with glutathione S-transferase produced in E coli. Recombinant proteins were puri®ed by anity chromatography on glutathione Sepharose, eluted with free glutathione and dialysed. As shown in Figure 7c , the three CDC25B phosphatases were able to activate a cdc2-cyclin B complex isolated from ®ssion yeast (see Materials and methods) although B1 seemed to be slightly more ecient. Phosphatase activities of the three variants were also measured according to (Homann et al., 1993) , with the modi®cation described in the Materials and methods section, using pNPP as substrate. As shown in Figure 7d , for concentrations of puri®ed phosphatase ranging from 1 to 10 mg of protein, recombinant CDC25B1 was slightly more active (1.5-fold) than CDC25B2 and CDC25B3.
Complementation of a thermosensitive allele of CDC25 in ®ssion yeast
Recently, it has been proposed that cytoplasmic accumulation of CDC25B is involved in the control of the initiation of mitosis in HeLa cells (Gabrielli et al., 1996) . Both CDC25B1 (Nagata et al., 1991) and CDC25B2 (this work) have been isolated by virtue of their ability to complement the mitotic function of a thermosensitive allele of cdc25 in ®ssion yeast. To compare the activity of the three splicing variants we therefore investigated their ability to behave as inducer of mitosis and to complement a thermosensitive cdc25 allele. All three variants were sub-cloned under the control of the constitutive ADH promoter and transformed in the ®ssion yeast strain SP587 carrying the cdc25-22 ts allele. In addition, two N-terminal truncated CDC25B proteins that were identi®ed in our initial screen were also examined. CDC25B-S2 and CDC25B-S6 encode truncated proteins that lack the ®rst 274 and 405 amino-acids respectively (CDC25B1 numbering), S6 is therefore identical to the no. 67-2 clone identi®ed by Nagata and colleagues and encodes only the catalytic domain of CDC25B. The complementing activity of these constructs was tested after colony streaking and transfer to non-permissive temperature (35.58C). As shown in Figure 8 , while the empty vector was indeed unable to support growth, all CDC25B constructs complemented the ®ssion yeast cdc25-22 ts allele and allowed the formation of colonies. However, cells containing CDC25B1 seemed to grow more slowly and thus this variant appears to be less eective in this assay than CDC25B2 and B3. In ®ssion yeast, overexpression of cdc25 + results in the appearance of the`wee' phenotype, that is cell division at reduced cell length (Russell and Nurse, 1986) . Accordingly, we measured the length of cells expressing the CDC25B variants in liquid culture at both 258C and at 35.58C (Table 1) . At permissive temperature, all constructs were able to induce mitosis at a smaller size than control cells transformed with the empty vector. The eect was most striking in the case of CDC25B2, and cells overexpressing CDC25B2 displayed an obvious reduction in cell size at mitosis (data not shown). At non permissive temperature, control cells were unable to divide and rapidly displayed a terminal cdc 7 phenotype. CDC25B2 and CDC25B-S6 (D405) transformed cells entered mitosis at a similar size at both presence or the absence of the two short 14 and 41 amino-acids domains that are encoded by the two alternatively spliced exons that we have identi®ed.
Discussion
In this article we report the identi®cation and characterisation of three CDC25B tyrosine phosphatase splicing variants. Functional complementation of a CDC25 thermosensitive allele in ®ssion yeast led to the identi®cation of a cDNA closely related to the CDC25B sequence reported by Galaktionov and Beach (1991) and . Following genomic sequence analysis and ampli®cations with various speci®c primers we reached the conclusion that both cDNAs were splicing variants of the same CDC25B gene which we now designate CDC25B1 (the original isolate) and CDC25B2 (this study). A third variant that carries both domains that were detected in CDC25B1 and CDC25B2 was also identi®ed by PCR in the Burkitt lymphoma cDNA library, by RT ± PCR in human ®broblasts and in other cell lines. We designate this variant CDC25B3. A careful database search in the EST tags sub-section revealed that a short CDC25 cDNA fragment containing both the 42 bp insertion (CDC25B2 speci®c) and the 123 bp insertion (CDC25B1 speci®c) had previously been sequenced from a 73 day post-natal infant whole brain cDNA library (Soares 1NIB). This sequence was deposited by the IMAGE consortium (accession number H14343). We performed a PCR ampli®cation using speci®c primers and a partial sequencing of that EST cDNA (data not shown) and found that it is identical to the CDC25B3 splicing variant that we have identi®ed.
Our results indicate that at least three CDC25B variants are derived from the alternative splicing of a single CDC25 pre-mRNA. The putative intron-exon structure of CDC25B in the region coding these splicing events is schematised in Figure 3c . Introns 1 and 2 are probably very large since we have not been able to amplify them with PCR. On the contrary, introns 3 and 4 are only 245 bp and 105 bp respectively. At this stage, one cannot exclude the possibility that the organisation of this gene is more complex, although we have not yet detected other size variants that may re¯ect the existence of additional splice sites. The two alternatively spliced exons are probably conserved in other vertebrates since the mouse CDC25B clone (M2-cdc25) reported by Kakizuka et al. (1992) is a CDC25B3 cDNA according to our nomenclature.
Splicing variants of other cell cycle regulatory proteins have also been recently reported. Twò PISLRE', CDK-related proteins that are probable splice variants of the same gene have been cloned (Brambilla and Draetta, 1994; Grana et al., 1994) and a cyclin E splicing variant that lacks 49 amino-acids within the cyclin box and is therefore unable to bind cdk2 has been found in several cell lines (Sewing et al., 1994) . Alternate splicing resulting in the production of a novel cyclin D1 transcript has also been identi®ed and appears to be modulated by A/G polymorphism located at the splice donor region of exon 4 (Betticher et al., 1995) . However, this polymorphism is not speci®c for tumour cells, although it might be associated with higher risk of non-small cell lung cancer relapse.
We have demonstrated here that alternative splicing play a role in the regulation of the CDC25B expression. What therefore are the mechanisms that regulate the alternative splicing of CDC25B (Green, 1991) , what are the splicing factors involved (Horowitz and Krainer, 1994) and are they speci®cally dedicated to CDC25B pre-mRNA? These are some of the questions that remain to be investigated.
The list of cyclin-dependent kinases that have been identi®ed so far is probably far from complete (Pines, 1995) . Therefore, the number of CDK-cyclin complexes that we are currently considering, with respect to their regulation through the activity of CDC25 phosphatases, is certainly largely underestimated. In our screen for suppressors of CDC25 thermosensitive mutation in ®ssion yeast we have been unable to identify CDC25 genes other than the already cloned CDC25A and CDC25B. We did not retrieve a CDC25C cDNA, but this result is not surprising since it has been reported that CDC25C does not fully rescue a cdc25-22 allele at strict non-permissive temperature (Jinno et al., 1994) . Similarly, we did not retrieve CDC25B1 in our initial screen and this is also likely to be due to its poor ability to complement a cdc25-22 ts allele at 35.58C. One should therefore consider the possibility that other human CDC25-related genes might exist but, as for CDC25C, they are not as potent as CDC25A and B in the complementation of a ®ssion yeast mitotic CDC25 defect. Other cloning strategies should therefore de®nitely be used to sort this question.
Whether or not other CDC25 genes exist, alternative splicing might be a major regulatory mechanism by which to generate a larger family of CDC25 proteins. These might share common features in their catalytic and structurally important domains but be divergent in domains that are speci®cally involved in other speci®c functions such as the regulation of catalytic activity or substrate recognition. In this report we have shown that CDC25B exon skipping is responsible for the presence or absence of two domains that are partially conserved in the human CDC25 gene family. These exons are shown to be important for the in vivo regulation of CDC25B activity. We have clearly demonstrated using the ®ssion yeast system that CDC25B2 is more ecient than CDC25B3 and CDC25B1, both as an inducer of mitosis and to rescue a thermosensitive allele of the CDC25 S pombe phosphatase. Our results suggest that the 14 amino- Splice variants of the CDC25B phosphatase V Baldin et al acid domain that is present in CDC25B2 had an activatory eect on the activity in vivo. In contrast, the 41 amino-acid domain that is speci®c for CDC25B1, appears to play an inhibitory role. In agreement with this model, the CDC25B3 phosphatase that carries both the 14 and the 41 residue insertions displays a intermediate activity. It has been shown recently in HeLa cells that the CDC25B phosphatase is involved in the control of the initiation of mitosis (Gabrielli et al., 1996) . Since in ®ssion yeast CDC25 is only required at the G 2 /M transition our results obtained in this model organism are likely to re¯ect the real properties of the three human CDC25B variants. It has been suggested by Xu and Burke (1996) that the amino-terminus of CDC25B is not required for the interaction of the phosphatase with the cyclin A-cdk2 complex, and has a negative regulatory eect on the CDC25 phosphatase activity (Xu and Burke, 1996) . We have also observed that a truncated version of CDC25B that carries only the catalytic domain, is an ecient tyrosine phosphatase that complements a cdc25-22 ts allele in ®ssion yeast. However, our results indicate that the regulatory function of the N-terminal domain of CDC25B is more subtle and that the splice variant forms of CDC25B have dierent activities in vivo.
As already demonstrated for CDC25A and CDC25C, CDC25B phosphatases are phosphorylated upon incubation with cellular extracts (data not shown), but the identity of the kinase that is involved in that process as well as the consequences of this phosphorylation on the two alternatively spliced exons remain unclear. Alternatively, it is possible that the two domains encoded by the spliced exons are involved in protein ± protein interaction and may for instance associate regulatory partners that modify the catalytic activities of these phosphatases. Alternative splicing might also be an important mechanism for the regulation of stability, or for the intracellular localisation of speci®c CDC25B sub-types, or for the ®ne tuning of the substrate speci®city of that class of enzymes toward the multiple CDK-cyclin complexes during the major transitions of the cell cycle. Further investigations are now needed to examine these dierent hypotheses.
On the basis of both expression studies and microinjection experiments, it was thought that CDC25B and C act as mitotic regulators in late G 2 while CDC25A is likely to function earlier in the cell cycle and be involved in the regulation of the cyclin dependent kinases that regulate G 1 /S transition (Jinno et al., 1994; . It has been shown by Gabrielli and co-workers that in HeLa cells, CDC25B is present in interphase but strongly increases in prophase and is involved in the regulation of prophase microtubules nucleation (Gabrielli et al., 1996) . Accordingly, we have shown here that the expression of CDC25B3 (and to a minor extend B1 and B2) are cell cycle regulated with a maximum in G 2 -phase. As shown in Figure 7 , the sizes of the three CDC25B variants are very similar (566, 539 and 580 residues for B1, B2 and B3 respectively), and most of the studies have been performed using antibodies that are unable to distinguish between the three splicing variants. In light of our results and depending on the expression of these three proteins in dierent cell types, it might be necessary to re-investigate with speci®c probes some of the ®ndings previously reported.
The overexpression of CDC25B phosphatase in human breast cancer has recently been reported (see introduction). That study was performed using a probe that could not distinguish between the three variants that we have identi®ed. It is now also essential to reconsider these results by investigating the speci®c expression of the three variants. Similarly, the demonstration of a potentially oncogenic role of CDC25B in association with Ras emphasises the importance of our ®ndings. Strikingly, CDC25B3 is the only variant that is expressed in primary ®broblasts whereas the three forms are present in immortalised ®broblasts. It is therefore crucial to determine whether the transforming activity of CDC25B is common to all the three members of the CDC25B family or is speci®c to one of the variants. The CDC25B gene was mapped by FISH to chromosome 20p13 (Demetrick and Beach, 1993; Lane et al., 1993) , an area which is not known to present karyotypic alteration in tumours. However, mutations of splice sites contributes signi®cantly to human genetic disease by aecting premRNA splicing. The study of the contribution of CDC25B splicing in carcinogenesis is therefore an important issue.
Materials and methods
cDNA library construction
The cDNA library used in this study is described in (Superti-Furga et al., 1996) . Brie¯y, that library was made from a Burkitt lymphoma B cell line called BJA-B. The complexity was 1610 6 original clones with a 1.5 kb average insert size. The S pombe vector pADH-X used carries the ura4+ gene and the ARS1 from Schizosaccharomyces pombe. The cDNA was cloned under the control of the constitutive S pombe ADH promoter.
Yeast strains, transformation and screening
The S pombe strain used in this study was SP587 (h+, ura4, ade6.210) , a gift of D Beach. Cells were grown in minimal supplemented media (BIO 101 Inc). Transformation of the cells with the cDNA library was performed by electroporation using the Biorad Genepulser as described (Prentice, 1992) . Transformants were plated on selective media and transferred at non permissive temperature (35.58C) after an overnight incubation at 258C. After 10 days, plasmids recovered from growing colonies were re-transformed to ensure the speci®city of complementation, then mapped and sequenced. A total of 20 clones that conferred the complementing activity were selected from approximately 4.7610 5 transformants, which is about 50% of the total complexity of the library.
Complementation assays were performed after transformation of the SP587 strain with the pADH-X vector alone or containing CDC25B splicing variant inserts. The clones S2 and S6 that encode N-terminal truncated (D274 and D405) forms of CDC25B were also used in that study. These partial clones were recovered from our initial screening. Colonies were streaked in duplicate on selective media and grown at 258C or 35.58C. To determine cell size at mitosis, cells were grown in liquid at permissive temperature and transferred at 35.58C for 6 h. A minimum of 50 cells with a complete septum were measured microscopically and the average+s.d. was calculated. Cytological observations were performed as described (Moreno et al., 1991) .
Polymerase chain reaction
Primers no. 1 to no. 6 were used to amplify CDC25B1, B2 and B3 from the Burkitt lymphoma library (100 ng) and from plasmid (10 ng). Primers no. 7 and no. 8 were used to amplify the genomic DNA that includes the sequence deleted in CDC25B2.
PCR products were obtained after 40 cycles (948C, 1.5 min; 608C, 1.5 min; 728C, 1.5 min) followed by 10 min extension at 728C using a temperature cycler (Biometra). The reactions were performed in 50 ml PCR buer containing 1 unit of Taq polymerase (Extrapol I, Eurobio), 100 mM each dNTP and 200 nM each primers. The reaction products were separated on 1 or 2% agarose gel (Eurobio).
RT ± PCR
Total RNA from 10 6 cells was prepared by using the Trizol reagent (Gibco BRL) following the manufacturer's instructions. RNA (1.5 mg) was ®rst incubated with random hexamer (10 mg/ml), heated 5 min at 958C and cooled 5 min on ice before addition of 100 Units of Maloney murine leukaemia virus reverse transcriptase (Promega), 2 U/ml RNAse inhibitor and 250 mM dNTP. A control without addition of reverse transcriptase was always performed to ensure that ampli®cation did not proceed from residual genomic DNA. PCR was subsequently performed as described above using 10 ml of the reverse transcription product per reaction.
The primers used to amplify simultaneously the three CDC25B splicing variants were the following: Primer no. 9: 5'-GCTTCCTCGCCGGTCACCAC-3' Primer no. 10:5'-CCTGCGGCTGGCCCACTC-3'
The primers used to amplify CDC2 were the following: Forward primer: 5'-GGATCTACCATACCATTGACT-3' Reverse primer: 5'-CAAGCCATTTTCATCCAAGTT-3'
Cell culture
Human diploid lung ®broblasts (IMR-90), HeLa cells, human spontaneously immortalised keratinocytes, and MDAH-041 Li ± Fraumeni ®broblasts (Agarwal et al., 1995) , were cultured in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% heat inactivated foetal calf serum (FCS), 2 mM glutamin, penicillin (100 U/ml) and streptomycin (100 mg/ml) in a humidi®ed atmosphere containing 5% CO 2 at 378C. Human breast adenocarcinoma cells (cell line MCF-7, (Mazars et al., 1995) ) were grown at 378C in RPMI 1640 medium supplemented with 5% FCS, 2 mM glutamin, insulin (1 mM) and gentamycin (25 mg/ml). Human spontaneously immortalised endometrium epithelial cells (PYC) and epithelioid sarcoma cell line (SARCCR2) (generous gifts of Dr S Jozan, Centre Claudius Regaud, Toulouse, France), IGROV1 human ovarian carcinoma cells (a gift of Dr J BeÂ nard, Villejuif) and NIH-OVCAR3 human ovarian carcinoma cells (ATCC HTB161) were cultured in the same condition as MCF7 cells.
Sequence analyses
Sequence editing, comparisons and alignments were performed using the Best®t and Gap software from the UWGCG package.
Expression and puri®cation of recombinant human CDC25B
Human CDC25B1, B2 and B3 were cloned in the pGEX-2T vector (Pharmacia) and expressed in Escherichia coli (TG1) as fusion with glutathione S-transferase. After isopropyl b-D-thiogalactoside (IPTG) induction (0.4 mM ®nal concentration) for 4 h at 258C, the three fusion proteins were recovered as described (Smith and Johnson, 1988) by anity chromatography on glutathione-Sepharose beads (Pharmacia) and eluted by 10 mM glutathione in 50 mM Tris-HCl, pH 8.0, 50 mM NaCl and 1 mM DTT. Eluted proteins were extensively dialysed overnight against the same buer in the absence of glutathione. Contamination of these preparations with the co-puri®ed 70 kDa dnaK E coli gene product (Yu-Sherman and Golberg, 1992) was quanti®ed by scanning densitometry and taken in account to calculate the actual CDC25B protein concentration.
Phosphatase assays
Phosphatase assays using cdc2 as substrate were performed as following: a ®ssion yeast strain carrying the cdc25-22 thermosensitive allele was transformed with the pREP1-cdc2HA vector encoding for the S pombe cdc2 kinase tagged with the HA epitope under the control of the thiamine repressible promoter (Basi et al., 1993) . Exponentially growing cells were shifted during 4.5 h at 35.58C to block their cell cycle at G 2 /M and the cells were harvested. Cell pellets were resuspended in three volumes of buer A (50 mM Tris HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% triton X100, 1 mM dithiothreitol (DTT) supplemented with proteases inhibitors: 5 mg/ml leupeptin, 2 mg/ml aprotinin, 20 mg/ml soybean trypsin inhibitor, 10 mg/ml tosyl lysine chloromethyl ketone (TLCK), 20 mg/ml tosyl phenylalanine chloromethyl ketone (TPCK), 17 mg/ml phenyl-methyl-sulfonyl¯uoride (PMSF), 1 mg/ml pepstatin and phosphatases inhibitors: 50 mM NaF, 1 mM Na 3 VO 4 , 100 mM b-glycerophosphate). The cells were lysed by vortexing in the presence of glass beads and the soluble proteins were recovered after three centrifugations (14 000 r.p.m., 10 min at 48C). The Cdc2-HA/cyclin B complexes were immunoprecipitated from 250 mg of proteins using monoclonal anti-HA antibodies for 1 h at 48C. After addition of rabbit polyclonal anti-mouse IgG (for 1 h at 48C) and centrifugation (5 min, 14 000 r.p.m. at 48C), the supernatants were incubated with 10 ml of protein-A-Sepharose for 1 h at 48C. The immunoprecipitates were then washed twice in buer A without phosphatases inhibitors and once in a phosphatase buer: 50 mM Tris HCl pH 7.5, 10 mM MgCl 2 and 1 mM DTT (Parker and Piwnica-Worms, 1992 ) then incubated for 15 min at 308C in a ®nal volume of 80 ml with phosphatase buer containing recombinant fusion protein GST-CDC25B1, GST-CDC25B2, GST-CDC25B3 or GST. The immunoprecipitates were washed three times with 1 ml of buer A without phosphatases inhibitors, once with kinase buer (50 mM Tris HCl pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 100 mM ATP). The kinase activity on H1 histone was assayed by 10 min incubation at 308C, in a ®nal volume of 25 ml kinase buer containing 0.5 mg/ml histone H1 and 5 mCi of [g 32 P]ATP. After SDS ± PAGE electrophoresis, the H1 histone proteins were excised from the gel and counted in Packard 16500 TR counter (Cerenkov eect).
For phosphatase assays with para nitro-phenyl phospate as substrate, the bacterially-expressed GST-CDC25B1, B2 or B3 proteins were incubated in a ®nal volume of 200 ml with 20 mM para nitro-phenyl phosphate (Boehringer), 0.1% b-mercaptoethanol, 1 mM EDTA, 50 mM Tris-HCl pH 8.2 for 20 min at 308C. The reaction was stopped through the addition of 800 ml 0.2 M NaOH and the absorbance at 410 nm was measured.
In vitro translation, electrophoresis and Western-blot
The CDC25B1-B3 open reading frame were cloned in the pET14b vector (Novagen) and the protein were in vitro translated in rabbit reticulocyte lysate using the TNT transcription and translation kit (Promega) in the presence of unlabelled aminoacids. After electrophoresis on 10% acrylamide SDS ± PAGE and transfer to nitro-cellulose, the CDC25B variants were detected by Western blot using rabbit polyclonal IgG raised against the carboxy terminus of mouse CDC25B (Santa Cruz, cat no. sc-326).
